N-Methyl-2C-B, or N-Me-2C-B, also known as 2C-B-M or 2C-BM, as well as 4-bromo-2,5-dimethoxy-N-methylphenethylamine, is a serotonin receptor modulator of the phenethylamine and 2C families. It is the N-methyl derivative of 2C-B.
Use and effects N-Methyl-2C-B has been tested in humans by P. Rausch and was reported to be completely inactive.
Pharmacology
Pharmacodynamics N-Methyl-2C-B showed affinity for the serotonin 5-HT2 receptors, specifically for the serotonin 5-HT2A and 5-HT2C receptors. Its affinities (Ki) were 2.9 nM for the DOI-labeled serotonin 5-HT2A receptor, 380 nM for the ketanserin-labeled serotonin 5-HT2A receptor, and 100 nM for the serotonin 5-HT2C receptor. These affinities were approximately 3-fold, 11-fold, and 3-fold lower than those of 2C-B, respectively.
History N-Methyl-2C-B was first described in the scientific literature by Richard Glennon and colleagues by 1994. It was encountered as a novel designer drug in Europe in 2014.
Society and culture
Legal status
Canada N-Methyl-2C-B is a controlled substance in Canada under phenethylamine blanket-ban language.
See also 2C (psychedelics) N-Ethyl-2C-B N-Methyl-2C-I Methyl-DOB (N-methyl-DOB) N-Methyl-DOI IDNNA (N,N-dimethyl-DOI) 25B-NB (N-benzyl-2C-B) 25B-NBOMe
References
External links N-Me-2C-B - Isomer Design


